Malaria

Tropical Infectious Diseases

Volumn 2, Issue , 2006, Pages 1024-1062

  Hoffman, Stephen L ^a,b   Campbell, Carlos C ^c   White, Nicholas J ^d,e  

^a SANARIA INC   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e BEN TAUB GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746815254     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06668-9.50095-8     Document Type: Chapter

References (134)

1. Breman JG, Egan A, Keusch GT The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg 2001, 64:iv-vii.
2. Sachs J, Malaney P The economic and social burden of malaria. Nature 2002, 415:680-685.
3. Gilles HM Historical outline. Essential Malariology 2002, 7. Arnold, London, ref 3. 4th ed. D.A. Warrell, H.M. Gilles (Eds.).
4. Honigsbaum M: The Fever Trail: In Search of the Cure for Malaria. Great Britain, Macmillan, May 2001.
5. Rocco F The Miraculous Fever Tree: Malaria and the Quest for the Cure That Changed the World 2003, HarperCollins, New York.
6. Laveran A Note sur un nouveau parasite trouve dans le sang de plusieurs malades atteints de fievre palustre. Bull Acad Med Ser 2 1880, 9:1235-1236.
7. Ross R On some peculiar pigmented cells found in two mosquitoes fed on malarial blood. BMJ 1897, 2:1786-1788.
8. Beadle C, Hoffman SL History of Malaria in the United States Naval Forces at War: World War I through the Vietnam Conflict. Clin Infect Dis 1993, 16:320-329.
9. Najera JA Malaria control: achievements, problems and strategies. Parassitologia 2001, 43:1-89.
10. Singh B, Sung LK, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004, 363:1017-1024.
11. Beier JC, Davis JR, Vaughan JA, et al. Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg 1991, 44:564-570.
12. Fairley NH Sidelights on malaria in man obtained by subinoculation experiments. Trans R Soc Trop Med Hyg 1947, 40:621-676.
13. Mota MM, Rodriguez A Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host. Cell Microbiol 2004, 6:1113-1118.
14. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984, 225:593-599.
15. Robson KJ, Hall JR, Jennings MW, et al. A highly conserved amino acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988, 335:79-82.
16. Rogers WO, Malik A., Mellouk S, et al. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci USA 1992, 89:9176-9180.
17. Mota MM, Hafalla JC, Rodriguez A Migration through host cells activates plasmodium sporozoites for infection. Nat Med 2002, 8:1318-1322.
18. Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum:. Science 1994, 264:1941-1944.
19. Baruch DI, Pasloske B, Singh HB, et al. Cloning the P. falciparum gene encoding PfMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995, 82:77-87.
20. Su XZ, Heatwole VM, Wertheimer SP, et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes. Cell Jul 14; 1995, 82:89-100.
21. Horrocks P, Pinches R, Christodoulou Z, et al. Variable var transition rates underlie antigenic variation in malaria:. Proc Natl Acad Sci USA 2004, 101:11129-11134.
22. Krotoski WA, Collins WE, Bray RS, et al. Demonstration of hypnozoites in sporozoite transmitted Plasmodium vivax infection. Am J Trop Med Hyg 1982, 31:1291-1293.
23. Krotoski WA The hypnozoite and malarial relapse. Prog Clin Parasitol 1989, 1:1-19.
24. Malaria Surveillance-United States, 2002. MMWR Surveill Summ 2004 Apr 30 2002, 53:21-34.
25. Miller LH, Mason SJ, Clyde DF, et al:The resistance factor to Plasmodium vivax in blacks: The Duffy-Blood-Group Genotype. FyFy N Engl J Med. 295: 302-304.
26. Chitnis CE, Miller LH Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994, 180:497-506.
27. Gardner MJ, Tettelin H, Carucci DJ, et al. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science 1998, 282:1126-1132.
28. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
29. Carlton JM, Angiuoli SV, Suh BB, et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 2002, 419:512-519.
30. Gardner MJ Parasite Genomics: Microbial Genomes 2004, Humana Press, Totowa, NJ.
31. Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
32. Lasonder E, Ishihama Y, Anderson JS, et al. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 2002, 419:537-542.
33. Le Roch KG, Zhou Y, Blair PL, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003, 301:1503-1508.
34. Bozdech Z, Zhu J, Joachimiak MP, et al. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol 2003, 4:R9.
35. Snow RW, Craig M, Deichmann U, et al. Estimating mortality, morbidity, and disability due to malaria in Africa's non-pregnant population. Bull World Health Organ 1999, 77:624-640.
36. MacDonald G The epidemiology and control of malaria 1957, Oxford University Press, London/New York.
37. Black RH Manual on epidemiology and epidemiological services in malaria programmes 1968, World Health Organization, Geneva.
38. Nagel R Innate resistance to malaria conferred by red cell genetic defects. Malaria: A Hematological Perspective 2004, 277-315. Imperial College Press, London. S.H. Abdalla, G. Pasvol, S.L. Hoffman (Eds.).
39. Bayoumi RA The sickle cell trait modifies the intensity and specificity of the immune response against Plasmodium falciparum malaria and leads to acquired protective immunity. Med Hypotheses 1987, 22:287-298.
40. Rihet P, Flori L, Tall F, et al. Hemoglobin C is associated with reduced Plasmodium falciparum parasitemia and low risk of mild malaria attack. Hum Mol Genet 2004, 13:1-6.
41. Baird JK Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 1998, 92:367-390.
42. Schofield L, Hewitt M, Evans K, et al. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789.
43. Cohen S, McGregor IA, Carrington S Gamma-globulin and acquired immunity to human malaria. Nature (London) 1961, 192:733-737.
44. Sabchareon AD, Outtara D, Burnouf T, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 45:297-308.
45. Hill A, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and the resistance to severe malaria. Nature (London) 1992, 360:434-439.
46. Baird JK, Owusu AS, Utz GC, et al. Seasonal malaria attack rates in infants and young children in northern Ghana. Am J Trop Med Hyg 2002, 66:280-286.
47. Owusu Agyei S, Koram KA, Baird JK, et al. Incidence of symptomatic and asymtomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg 2001, 65:197-203.
48. Hoffman SL, Oster CN, Plowe CV, et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987, 237:639-642.
49. Beier JC, Oster CN, Onyango FK, et al. Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg 1994, 50:529-536.
50. Phillips-Howard PA, Nahlen BL, Wannemuehler KA, et al. Impact of permethrin-treated bed nets on the incidence of sick child visits to peripheral health facilities. Am J Trop Med Hyg 2003, 68:38-43.
51. Zucker JR, Lackritz EM, Ruebush TK, et al. Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg 1996, 5:655-660.
52. Steketee RW, Nahlen BL, Parise ME, et al. The burden of malaria in pregnancy in sub-Saharan Africa. Am J Trop Med Hyg 2001, 641(Suppl 2):28-35.
53. Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004, 71(Suppl 2):41-54.
54. Control of Tropical Diseases: Severe and Complicated Malaria, 2nd ed. Trans R Soc Trop Med Hyg 1990, 84(Suppl 2):1-65. World Health Organization.
55. Luxemburger C, Ricci F, Nosten F, et al. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg 1997, 91:256-262.
56. Hoffman SL, Piessens WF, Ratiwayanto S, et al. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med 1984, 310:337-341.
57. Kwiatkowski D, Hill AVS, Sambou I, et al. TNF concentrations in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990, 336:1201-1204.
58. Day NPJ, Hien TT, Schollaardt, et al. The prognostic and pathophysiological role of pro- and anti-inflammatory cytokines in severe malaria. J Infect Dis 1999, 180:1288-1297.
59. McGuire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994, 371:508-510.
60. Hananantachai H, Patarapotikul J, Looareesuwan S, et al. Lack of association of -308A/G TNFA promoter and 196R/M TNFR2 polymorphisms with disease severity in Thai adult malaria patients. Am J Med Genet 2001, 102:391-392.
61. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Path 1999, 155:395-410.
62. Roberts DJ, Craig AG, Berendt AR, et al. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 1992, 357:689-692.
63. Barnwell JW, Asch AS, Nachman RL, et al. A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum infected erythrocytes. J Clin Invest 1989, 84:765-772.
64. Turner GDH, Morrison H, Jones M, et al. An immunohistochemical study of the pathology of fatal malaria: evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994, 145:1057-1069.
65. Yipp BG, Anand S, Schollaardt T, et al. Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. Blood 2000, 96:2292-2298.
66. Fried M, Duffy PE Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996, 272:1502-1504.
67. Fried M, Nosten F, Brockman A, et al. Maternal antibodies block malaria. Nature 1998, 395:851-852.
68. Udomsangpetch R, Wahlin B, Carlson J, et al. Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte rosettes. J Exp Med 1989, 169:1835-1840.
69. Carlson J, Helmby H, Hill AVS, et al. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet 1990, 336:1457-1460.
70. Pain A, Ferguson DJ, Kai O, et al. Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc Natl Acad Sci USA 2001, 98:1805-1810.
71. Dondorp AM, Angus BJ, Hardeman MR, et al. Prognostic significance of reduced red cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997, 57:507-511.
72. Looareesuwan S, Wilairatana P, Krishna S, et al. Magnetic resonance imaging of the brain in cerebral malaria. Clin Infect Dis 1995, 21:300-309.
73. Newton CR, Peshu N, Kendall B, et al. Brain swelling and ischaemia in Kenyans with cerebral malaria. Arch Dis Child 1994, 70:281-287.
74. Newton CR, Hien TT, White NJ Cerebral malaria. J Neurol Neurosurg Psychiatry 2000, 69:433-441.
75. Day NP, Phu NH, Mai NT, et al. Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Crit Care Med 2000, 28:1353-1362.
76. Charoenpan P, Indraprasit S, Kiatboonsri S, et al. Pulmonary edema in severe falciparum malaria: hemodynamic study and clinicophysiologic correlation. Chest 1990, 9:1190-1197.
77. Sowunmi A, Newton CR, Waruiru C, et al. Arginine vasopressin secretion in Kenyan children with severe malaria. J Trop Pediatr 2000, 46:195-199.
78. Price RN, Simpson J, Nosten F, et al. Factors contributing to anemia in uncomplicated falciparum malaria. Am J Trop Med Hyg 2001, 65:614-622.
79. Skudowitz RB, Katz J, Lurie A, et al. Mechanisms of thrombocytopenia in malignant tertian malaria. BMJ 1973, 2:515-518.
80. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000, 182:629-633.
81. Day NP, Phu NH, Mai NT, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000, 28:1833-1840.
82. Taylor TE, Borgstein A, Molyneux ME Acid-base status in paediatric Plasmodium falciparum malaria. Q J Med 1993, 86:99-109.
83. Agbenyega T, Angus BJ, Bedu-Addo G, et al. Glucose and lactate kinetics in children with severe malaria. J Clin Endocrinol Metab 2000, 85:1569-1576.
84. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycaemia and hyperinsulinaemia in falciparum malaria. N Engl J Med 1983, 309:61-66.
85. White NJ, Miller KD, Marsh K, et al. Hypoglycaemia in African children with severe malaria. Lancet 1987, 1:708-711.
86. Taylor TE, Molyneux ME, Wirima JJ, et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine in severe falciparum malaria. N Engl J Med 1988, 319:1040-1047.
87. Brabin BJ Analysis of malaria in pregnancy in Africa. Bull World Health Organ 1983, 61:1005-1016.
88. Nosten F, McGready R, Simpson JA, et al. The effects of Plasmodium vivax malaria in pregnancy. Lancet 1999, 354:546-549.
89. Rickman LS, Long GW, Oberst R, et al. Rapid diagnosis of malaria by acridine orange staining of centrifuged parasites. Lancet 1989, 1:68-71.
90. Schneider P, Wolters L, Schoone G, et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol 2005, 43:402-405.
91. Shiff CJ, Minjas J, Premji Z The ParaSight(R)-F test: a simple rapid manual dipstick test to detect Plasmodium falciparum infection. Parasitol Today 1994, 10:494-495.
92. Beadle C, Long GW, Weiss WR, et al. Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet 1994, 343:564-568.
93. Piper R, Lebras J, Wentworth L, et al. Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase (pLDH). Am J Trop Med Hyg 1999, 60:109-118.
94. Field JW, Niven JC A note on prognosis in relation to parasite counts in acute subtertian malaria. Trans R Soc Trop Med Hyg 1939, 30:569-574.
95. Silamut K, White NJ The relationship of stage of parasite development to prognosis in falciparum malaria. Trans R Soc Trop Med Hyg 1993, 87:436-443.
96. Phu NH, Day NPJ, Diep TS, et al. Intraleukocytic malaria pigment and prognosis in severe malaria. Trans R Soc Trop Med Hyg 1995, 89:197-199.
97. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000, 356:297-302.
98. White NJ Assessment of the pharmacodynamic properties of the antimalarial drugs in vivo. Antimicrob Agents Chemother 1997, 41:1413-1422.
99. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993, 341:1054-1056.
100. Trape JF The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001, 64(Suppl 1-2):12-17.
101. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993, 341:96-100.
102. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997, 56:621-626.
103. Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995, 171:1678-1682.
104. Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002, 360:58-60.
105. Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002, 35:e92-e95.
106. Baird JK, Hoffman SL Primaquine therapy for malaria. Clin Infect Dis 2004, 39:1336-1345.
107. Newton CR, Chokwe T, Schellenberg JA, et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997, 91:161-165.
108. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 2001, 95:637-650. Artemether-Quinine Meta-analysis Study Group.
109. Hien TT, Arnold K, Vinh H, et al. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Trans R Soc Trop Med Hyg 1992, 86:582-583.
110. Phuong CXT, Bethell DB, Phuong PT, et al. Comparison of artemisinin suppositories, intramuscular artesunate, and intravenous quinine for the treatment of severe childhood malaria. Trans R Soc Trop Med Hyg 1997, 91:335-342.
111. Nosten F, van Vugt M, White NJ Intrarectal artemisinin derivatives. Med Trop (Mars) 1998, 58(Suppl 3):63-64.
112. Baird JK, Fryauff DJ, Hoffman SL Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003, 37:1659-1667.
113. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003, 36:541-549.
114. Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002, 35:825-833.
115. Fryauff DJ, Baird JK, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995, 346:1190-1193.
116. National Center for Infectious Diseases: Traveler's Health. Available at 5/15/05. http://www.cdc.gov/travel/.Accessed.
117. Alonso PL, Lindsay SW, Armstrong JRM, et al. The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet 1991, 337:1499-1502.
118. Lengeler C Insecticide-treated bednets and curtains for preventing malaria (Cochrane Review). The Cochrane Library, Issue 2 2003, Update Sofware, Oxford.
119. Roll Back Malaria Partnership: RBM Consensus Statement on Insecticide Treated Netting. March 2004. Available at. Accessed 2/14/05. http://rbm.who.int/partnership/wg/wg_itn/docs/RBMWINStatementVector.pdf.
120. Goodman CA, Coleman P, Mills A Cost effectiveness of malaria control in sub-Saharan Africa. Lancet 1999, 354:378-385.
121. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998, 59:813-822.
122. Kayentao K, Kodio M, Newman RD, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis 2005, 191:109-116.
123. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, ASM Press, Washington, DC. S.L. Hoffman (Ed.).
124. Richie TL, Saul A Progress and challenges for malaria vaccines. Nature 2002, 415:694-701.
125. Long CA, Hoffman SL Parasitology. Malaria-from infants to genomics to vaccines. Science 2002, 297:345-347.
126. Hoffman SL Save the children. Nature 2004, 430:2-3.
127. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
128. Luke TC, Hoffman SL Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003, 206:3803-3808.
129. World Health Organization: Immunizations, Vaccines and Biologicals. Available at. Accessed 2/14/05. http://www.who.int/vaccines/en/aboutus.shtml.
130. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoites of the human malaria parasite Plasmodium falciparum. Science 1984, 225:593-599.
131. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumspzorozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997, 336:86-91.
132. Kester KE, McKinney DA, Tornieporth N, et al. RTS,S Malaria Vaccine Evaluation Group. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001, 183:640-647.
133. Alonso P, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02 vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
134. Hoffman SL, Subramanian GM, Collins FH, Venter JC Plasmodium, human and Anopheles genomics and malaria. Nature 2002, 415:702-709.